EcoDrugPlus

Adrenoceptor Alpha 2b

Ensembl ID : ENSPMRG00000009430
Gene Symbol: ADRA2B
3 Cross references
219 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adrenoceptor Alpha 2c

Ensembl ID : ENSPMRG00000016353
Gene Symbol: ADRA2C
1 Cross references
227 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adrenoceptor Beta 1

Ensembl ID : ENSPMRG00000002282
Gene Symbol: ADRB1
3 Cross references
161 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adrenoceptor Beta 2

Ensembl ID : ENSPMRG00000015071
Gene Symbol: ADRB2
3 Cross references
263 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Adrenoceptor Beta 3

Ensembl ID : ENSPMRG00000018633
Gene Symbol: ADRB3
3 Cross references
215 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Alcohol Dehydrogenase 5 (Class Iii), Chi Polypeptide

Ensembl ID : ENSPMRG00000011223
Gene Symbol: ADH5
1 Cross references
406 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Aldo-Keto Reductase Family 1 Member B

Ensembl ID : ENSPMRG00000023476
Gene Symbol: AKR1B1
3 Cross references
430 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Alpha Glucosidase

Ensembl ID : ENSPMRG00000002215
Gene Symbol: GAA
3 Cross references
234 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Amiloride-Sensitive Amine Oxidase [Copper-Containing]-Like

Ensembl ID : ENSPMRG00000023343
Gene Symbol: LOC114607667
2 Cross references
230 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Amine Oxidase Copper Containing 2

Ensembl ID : ENSPMRG00000011274
Gene Symbol: AOC2
2 Cross references
358 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Amyloid Beta Precursor Protein

Ensembl ID : ENSPMRG00000002927
Gene Symbol: APP
3 Cross references
276 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Androgen Receptor

Ensembl ID : ENSPMRG00000023019
Gene Symbol: AR
1 Cross references
276 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).